Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
NUTROPIN is a recombinant human growth hormone (somatropin) approved in 1994 for treating growth disorders and related conditions. Administered via injection, it replaces or supplements endogenous growth hormone in patients with deficiency or dysfunction. The cytokine modality directly addresses the underlying physiological deficit in GH-responsive populations.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely scaling defensively and exploring life-cycle management strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
Worked on NUTROPIN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings indicate minimal active hiring; roles available typically involve defending market share against biosimilars and optimizing payer relationships. Career development on NUTROPIN focuses on lifecycle management expertise rather than growth opportunities.